Epigenomics AG to Participate in Raymond James Human Health Innovations Conference

DGAP-News: Epigenomics AG

/ Key word(s): Conference/Miscellaneous

16.06.2020 / 10:00

The issuer is solely responsible for the content of this announcement.

Epigenomics AG to Participate in Raymond James Human Health Innovations Conference

Berlin (Germany) and San Diego, CA (U.S.A.), June 16, 2020 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”) today announced that company management will be presenting at the Raymond James Human Health Innovations Conference on Thursday, June 18, 2020, at 9:40 am (ET) / 3:40 pm (CET) and invites investors to participate by webcast. The webcast can be accessed in the investor relations section of Epigenomics’ website at https://www.epigenomics.com/news-investors/financial-calendar/.

 

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epi proLung(R) and HCCBloodTest, blood-based tests for lung and liver cancer detection, has received CE mark in Europe.

For more information, visit www.epigenomics.com.

 

Contact
Company

Epigenomics AG, Geneststraße 5, 10829 Berlin
Phone +49 (0) 30 24345 0
Fax +49 (0) 30 24345 555
E-Mail: contact@epigenomics.com

Investor Relations
IR.on AG
Frederic Hilke
Phone +49 221 9140 970
E-Mail: ir@epigenomics.com

 

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

 


16.06.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Epigenomics AG
Geneststraße 5
10829 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A11QW50
WKN: A11QW5
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1070737

 
End of News DGAP News Service

show this